Patients with T2D and high cardiovascular risk receive SGLT2 inhibitor or sulfonylurea for 30 days, with NLRP3 inflammasome activation analyzed in macrophages. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.